Please assess the completion status of the following clinical trial:

Trial Title: Effect of Milnacipran on Pain in Fibromyalgia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 18 or older~* Written informed consent and written release of health and research study information~* Diagnosis of Fibromyalgia~* Participant has pain greater than 4 on the NRS of 0 to 10 on average over the last week prior to initial evaluation that interferes with function most days per week~* Pain duration greater than 6 months~* Negative urine pregnancy test on experimental day 1 and 2 and on first day of treatment prior to administration of study medication and fluoroscopy~* Ability to speak and understand English, to follow instructions, and fill out study questionnaires~* Likely to complete all required visits~* Must be ambulatory and able to lay prone for 30 minutes~Exclusion Criteria:~* Any condition or situation that in the investigator's opinion may put the participant at significant risk, confound the study results, or interfere significantly with the participant's participation in the study~* Serious, unstable medical illness that could lead to hospitalization over the next three months; and/or a DSM-IV diagnosis(es) with active problems within the last six months, such as: schizophrenia, bipolar disorder, antisocial personality disorder, or substance use disorder~* Known, uncontrolled, serious systemic disease, including: hypertension and/or tachyarrythmia~* Females who are pregnant, breast feeding, or who plan to become pregnant, or who may potentially become pregnant~* Allergy or sensitivity to any component of the study medication or to contrast dye~* Patients on coumadin, heparin, or any other known increase risk of bleeding~* Signs of increased intracranial pressure~* Patients who are unable to continue current pain medication~* Allergy or contraindication to acetaminophen~* Use of monoamine oxidase inhibitors~* Uncontrolled narrow-angle glaucoma

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Titrated Milnacipram doses

Based on this trial design, predict the completion outcome and termination type (if applicable).